id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
EPA-R04-OAR-2018-0792-0014,EPA,EPA-R04-OAR-2018-0792,Ascend -12-2-19 ADEM email,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:39:54Z,,0,0,0900006484204be2
EPA-R04-OAR-2018-0792-0011,EPA,EPA-R04-OAR-2018-0792,06-18-2015 2014 EMIS INV,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:39:29Z,,0,0,09000064841f0490
EPA-R04-OAR-2018-0792-0008,EPA,EPA-R04-OAR-2018-0792,2016-AirEmissionsReport-2,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:38:40Z,,0,0,09000064841f05ac
EPA-R09-OAR-2019-0598-0002,EPA,EPA-R09-OAR-2019-0598,"Docket Index - Oscar Renda Contracting, Inc. General Permit",Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:42:03Z,,0,0,090000648425c468
EPA-R04-OAR-2018-0792-0010,EPA,EPA-R04-OAR-2018-0792,BEC Flare Hr 2013-2015,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:39:42Z,,0,0,09000064841f0488
EPA-R04-OAR-2018-0792-0006,EPA,EPA-R04-OAR-2018-0792,AL Cover Letter September 5-2019,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:39:05Z,,0,0,09000064841f05aa
EPA-R04-OAR-2018-0792-0007,EPA,EPA-R04-OAR-2018-0792,Responses to EPA re Alabama SO2 Transport,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:38:53Z,,0,0,09000064841f05ab
EPA-R08-OAR-2018-0380-0012,EPA,EPA-R08-OAR-2018-0380,Email Notif Final Permit to Affected States and Stakeholders,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:41:32Z,,0,0,090000648425f13f
EPA-R04-OAR-2018-0792-0002,EPA,EPA-R04-OAR-2018-0792,AL-SO2-Transport-SIP-Admin-Part1,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:40:31Z,,0,0,09000064838ea155
EPA-R09-OAR-2019-0598-0006,EPA,EPA-R09-OAR-2019-0598,"Approval for Oscar Renda Contracting, Inc. Portable Concrete Batch Plant Facility General Permit",Other,,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2020-01-01T01:42:18Z,,0,0,090000648425c469
EPA-R09-OAR-2019-0598-0004,EPA,EPA-R09-OAR-2019-0598,Section 2 - Final Permit and Related Documents,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:42:48Z,,0,0,090000648425bb19
EPA-R04-OAR-2018-0792-0012,EPA,EPA-R04-OAR-2018-0792,06-25-2014 2013 EMIS INV,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:39:17Z,,0,0,09000064841f0491
EPA-R04-OAR-2018-0792-0009,EPA,EPA-R04-OAR-2018-0792,01-28-2016 -CMS-FLARE RPT,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:38:27Z,,0,0,09000064841f05ad
EPA-R04-OAR-2018-0792-0015,EPA,EPA-R04-OAR-2018-0792,AL-117-PR-TSD-Escambia,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:38:03Z,,0,0,090000648420cf5c
EPA-HQ-OPP-2013-0153-0043,EPA,EPA-HQ-OPP-2013-0153,Aerobic Degradation of Chloropicrin in Aquatic Systems Data Evaluation Record (DER),Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:35:37Z,,0,0,0900006483aa9830
EPA-R04-OAR-2018-0792-0003,EPA,EPA-R04-OAR-2018-0792,AL-SO2-Transport-SIP-Ozone-Part2,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:40:43Z,,0,0,09000064838ea156
EPA-R04-OAR-2019-0156-0019,EPA,EPA-R04-OAR-2019-0156,AL-116-SIP Submittal-Admin-Part1,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:41:07Z,,0,0,090000648425e167
EPA-R04-OAR-2018-0792-0001,EPA,EPA-R04-OAR-2018-0792,Air Quality State Implementation Plans; Approvals and Promulgations: Alabama; 2010 1-Hour SO2 NAAQS Transport Infrastructure,Proposed Rule,,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-31T04:59:59Z,2020-01-27T02:01:58Z,2019-28236,0,0,090000648425d49a
EPA-R04-OAR-2018-0792-0013,EPA,EPA-R04-OAR-2018-0792,06-29-2016 2015 EMIS INV RPT,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:38:15Z,,0,0,09000064841f06a2
EPA-R09-OAR-2019-0598-0003,EPA,EPA-R09-OAR-2019-0598,Section 1 - Request for Coverage,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:41:50Z,,0,0,090000648425b000
EPA-R09-OAR-2019-0598-0005,EPA,EPA-R09-OAR-2019-0598,Section 3 – Supporting Documents,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:42:32Z,,0,0,090000648425bb1a
EPA-R04-OAR-2019-0156-0020,EPA,EPA-R04-OAR-2019-0156,SC_Ozone_iSIP_20180907,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:40:55Z,,0,0,090000648425e1b4
EPA-R08-OAR-2018-0380-0011,EPA,EPA-R08-OAR-2018-0380,Email Notif Final Permit to Permittee,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:41:20Z,,0,0,090000648425eb6a
EPA_FRDOC_0001-24895,EPA,EPA_FRDOC_0001,Meetings: Chartered Science Advisory Board,Notice,,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-18T04:59:59Z,2020-01-18T02:03:03Z,2019-28012,0,0,090000648425d44d
EPA-R06-OAR-2018-0705-0013,EPA,EPA-R06-OAR-2018-0705,"NM079.13 Proposed rule; extension of comment period; Air Quality State Implementation Plans; Approvals and Promulgations: New Mexico; Interstate Transport Requirements for the 2008 Ozone National Ambient Air Quality Standards (NAAQS), 1 page.",Proposed Rule,,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-18T04:59:59Z,2020-01-18T02:00:50Z,2019-27865,0,0,090000648425d4e8
EPA-R04-OAR-2018-0792-0004,EPA,EPA-R04-OAR-2018-0792,AL-SO2-Transport-SIP-SO2part-Part3,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:40:18Z,,0,0,09000064838ea157
EPA-HQ-OPP-2013-0153-0044,EPA,EPA-HQ-OPP-2013-0153,Environmental Chemistry Methods (ECM) and Independent Laboratory Validation (ILV) for Chloropicrin Data Evaluation Records (DERs),Supporting & Related Material,Evaluation,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:35:24Z,,0,0,0900006483aa9831
EPA-R04-OAR-2018-0792-0005,EPA,EPA-R04-OAR-2018-0792,June 6 2019 ADEM Email,Supporting & Related Material,,2019-12-31T05:00:00Z,2019,12,,,2020-01-01T01:40:06Z,,0,0,0900006483db751c
FDA-2019-H-6024-0001,FDA,FDA-2019-H-6024,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:24:25Z,,0,0,090000648425dd71
FDA-2011-N-0902-0014,FDA,FDA-2011-N-0902,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:53:14Z,2019-28249,0,0,090000648425db88
FDA-2019-H-6009-0001,FDA,FDA-2019-H-6009,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:23:23Z,,0,0,090000648425d8b7
FDA-2019-P-6100-0004,FDA,FDA-2019-P-6100,Attachment C- The Classic Reprint: The Use and Uses of Large Split Skin Grafts of Intermediate Thickness re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:18:17Z,,0,0,090000648425e4dd
FDA-2019-P-6100-0005,FDA,FDA-2019-P-6100,"Attachment D- 50 Years of Burn Care at Shriners Hospitals for Children, Galveston re: Citizen Petition from American Association of Tissue Banks",Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:18:30Z,,0,0,090000648425e4de
FDA-2019-P-6100-0002,FDA,FDA-2019-P-6100,Attachment A- The Classic Reprint re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:15:06Z,,0,0,090000648425e4db
FDA-2019-P-6099-0001,FDA,FDA-2019-P-6099,Citizen Petition from George M. Stone on behalf of Patients for Access to Advanced Therapy for Hemophilia,Other,Citizen Petition,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2024-11-12T23:15:15Z,,1,0,090000648425e1d0
FDA-2019-P-6100-0009,FDA,FDA-2019-P-6100,"Attachment H- Pelvic, Abdominal, and Chest Wall Reconstruction with Allo Derm in Patients at Increased Risk for Mesh-Related Complications re: Citizen Petition from American Association of Tissue Banks",Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:19:20Z,,0,0,090000648425e54c
FDA-2019-P-6100-0008,FDA,FDA-2019-P-6100,Attachment G- Sterile Decellularized Dermis - Instructions for Use re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:19:07Z,,0,0,090000648425e54b
FDA-2018-N-4839-0003,FDA,FDA-2018-N-4839,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:56:25Z,2019-28249,0,0,090000648425d8b1
FDA-2013-N-0662-0009,FDA,FDA-2013-N-0662,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:53:40Z,2019-28249,0,0,090000648425db89
FDA-2019-N-5955-0001,FDA,FDA-2019-N-5955,International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; AB-FUBINACA; 5FAMB- PINACA; 5F-MDMB-PICA; 4-FMDMB- BINACA; 4-CMC; Nethylhexedrone; alpha-PHP; DOC; Crotonyl Fentanyl; Valeryl Fentanyl; Flualprazolam and Etizolam; Request for Comments,Notice,Request for Comments,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-31T04:59:59Z,2020-02-01T02:02:04Z,2019-28269,0,0,090000648425d40c
FDA-2018-D-1459-0047,FDA,FDA-2018-D-1459,"Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed at One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual- Column Labeling, and Miscellaneous Topics; Guidance for Industry; Availability",Rule,Notice of Interim Rule,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:10:26Z,2019-27868,0,0,090000648425d410
FDA-2019-P-3877-0003,FDA,FDA-2019-P-3877,"Determination That GLUCOPHAGE (Metformin Hydrochloride) Oral Tablets, 500 Milligrams, 850 Milligrams, and 1 Gram, and GLUCOPHAGE XR (Metformin Hydrochloride) Oral Extended-Release Tablets, 500 Milligrams and 750 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:31:28Z,2019-28270,0,0,090000648425d320
FDA-2019-V-6101-0001,FDA,FDA-2019-V-6101,Variance Application from Donovan Rosling Rosling,Other,Application for Variance (VAR),2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T19:37:37Z,,0,0,090000648425ea93
FDA-2019-H-6023-0001,FDA,FDA-2019-H-6023,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:21:50Z,,0,0,090000648425db8b
FDA-2019-V-6101-0002,FDA,FDA-2019-V-6101,Acknowledgment Letter from FDA DMS to Donovan Rosling Rosling,Other,Acknowledgement Letter/Receipt,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T19:40:18Z,,0,0,090000648425eaab
FDA-2019-H-6021-0001,FDA,FDA-2019-H-6021,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T19:37:18Z,,0,0,090000648425e0c7
FDA-2019-P-6100-0001,FDA,FDA-2019-P-6100,Citizen Petition from American Association of Tissue Banks,Other,Citizen Petition,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2022-08-25T19:59:25Z,,0,0,090000648425e332
FDA-2019-P-6100-0015,FDA,FDA-2019-P-6100,"Attachment R- The use of a cellular dermal matrix in breast reconstruction
evolution of techniques over 2 decades re: Citizen Petition from American Association of Tissue Banks",Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:22:44Z,,0,0,090000648425e552
FDA-2019-P-6100-0003,FDA,FDA-2019-P-6100,Attachment B- Early Care of Burns re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:15:26Z,,0,0,090000648425e4dc
FDA-2019-P-6100-0011,FDA,FDA-2019-P-6100,Attachments J Through N re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:21:10Z,,0,0,090000648425e54e
FDA-2019-P-6100-0007,FDA,FDA-2019-P-6100,"Attachment F- Decellularization Strategies for Regenerative Medicine:
From Processing Techniques to Applications re: Citizen Petition from American Association of Tissue Banks",Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:18:55Z,,0,0,090000648425e4e0
FDA-2019-P-6100-0010,FDA,FDA-2019-P-6100,Attachment I- Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:20:08Z,,0,0,090000648425e54d
FDA-2019-P-6100-0012,FDA,FDA-2019-P-6100,Attachment O- Achilles Tendon Augmented Repair Using Human Acellular Dermal Matrix: A Case Series re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:22:03Z,,0,0,090000648425e54f
FDA-2019-N-0549-0011,FDA,FDA-2019-N-0549,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:54:45Z,2019-28249,0,0,090000648425d866
FDA-2016-N-3586-0005,FDA,FDA-2016-N-3586,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Focus Groups About Drug Products as Used by the Food and Drug Administration,Notice,30 Day Proposed Information Collection,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-31T04:59:59Z,2019-12-31T14:36:48Z,2019-28247,0,0,090000648425d323
FDA-2019-H-5989-0001,FDA,FDA-2019-H-5989,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T17:25:03Z,,0,0,090000648425e60c
FDA-2019-H-5984-0001,FDA,FDA-2019-H-5984,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:44:31Z,,0,0,090000648425e092
FDA-2019-H-5983-0001,FDA,FDA-2019-H-5983,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:43:38Z,,0,0,090000648425e3cf
FDA-2019-H-5411-0001,FDA,FDA-2019-H-5411,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:29:24Z,,0,0,090000648425d957
FDA-2019-V-6105-0001,FDA,FDA-2019-V-6105,Variance Application from ETS Pro Lighting INC,Other,Application for Variance (VAR),2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T22:06:45Z,,0,0,090000648425f5f2
FDA-2019-H-6006-0001,FDA,FDA-2019-H-6006,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:42:40Z,,0,0,090000648425e37b
FDA-2019-H-5946-0001,FDA,FDA-2019-H-5946,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:17:22Z,,0,0,090000648425e139
FDA-2019-P-6100-0018,FDA,FDA-2019-P-6100,Attachment U Part 1- The use of acellular dermal matrix in breast reconstruction: evolution of techniques over 2 decades re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:23:24Z,,0,0,090000648425e4f4
FDA-2019-P-6100-0016,FDA,FDA-2019-P-6100,Attachment S- Market Recap: Q418/FY18 Market Recap: US Surgical Matrices re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:23:00Z,,0,0,090000648425e553
FDA-2019-H-6011-0001,FDA,FDA-2019-H-6011,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:43:34Z,,0,0,090000648425d8f5
FDA-2019-P-3877-0004,FDA,FDA-2019-P-3877,Response Letter to Harman Finochem Limited Updated from FDA CDER,Other,Agency Response,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T19:24:26Z,,0,0,090000648425fa9c
FDA-2019-H-5988-0001,FDA,FDA-2019-H-5988,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:56:53Z,,0,0,090000648425e227
FDA-2019-P-6100-0020,FDA,FDA-2019-P-6100,Attachment V Shuren Letter re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:23:57Z,,0,0,090000648425e4f6
FDA-2019-P-6100-0019,FDA,FDA-2019-P-6100,"Attachment U Part 2- Prepectoral Breast Reconstruction with Fenestrated
Acellular Dermal Matrix: A Novel Design re: Citizen Petition from American Association of Tissue Banks",Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:23:45Z,,0,0,090000648425e4f5
FDA-2013-N-0134-0149,FDA,FDA-2013-N-0134,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:47:33Z,2019-28249,0,0,090000648425d409
FDA-2013-N-0242-0015,FDA,FDA-2013-N-0242,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:54:02Z,2019-28249,0,0,090000648425db8d
FDA-2019-P-6099-0002,FDA,FDA-2019-P-6099,Acknowledgment Letter from FDA DMS to George M. Stone,Other,Acknowledgement Letter/Receipt,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2020-08-05T19:12:41Z,,0,0,090000648425e1d2
FDA-2019-H-5987-0001,FDA,FDA-2019-H-5987,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:20:45Z,,0,0,090000648425db34
FDA-2019-H-6012-0001,FDA,FDA-2019-H-6012,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T19:36:06Z,,0,0,090000648425dde9
FDA-2019-H-5985-0001,FDA,FDA-2019-H-5985,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:28:56Z,,0,0,090000648425d6c8
FDA-2019-P-6100-0021,FDA,FDA-2019-P-6100,Acknowledgment Letter from FDA DMS to American Association of Tissue Banks,Other,Acknowledgement Letter/Receipt,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2020-01-02T14:23:18Z,,0,0,090000648425dfef
FDA-2019-P-6100-0017,FDA,FDA-2019-P-6100,Attachment T AATB Letter re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:23:12Z,,0,0,090000648425e554
FDA-2019-N-1517-0005,FDA,FDA-2019-N-1517,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:54:26Z,2019-28249,0,0,090000648425d865
FDA-2012-N-0477-0011,FDA,FDA-2012-N-0477,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:55:36Z,2019-28249,0,0,090000648425d86a
FDA-2016-D-2565-0018,FDA,FDA-2016-D-2565,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T14:56:03Z,2019-28249,0,0,090000648425d8ae
FDA-2013-N-0719-0008,FDA,FDA-2013-N-0719,Guidance for Industry on Planning for the Effects of High Absenteeism To Ensure Availability of Medically Necessary Drug Products,Other,Guidance,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2024-11-12T23:15:15Z,,1,0,090000648425e08e
FDA-2019-H-5986-0001,FDA,FDA-2019-H-5986,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:19:25Z,,0,0,090000648425d794
FDA-2016-N-4319-0004,FDA,FDA-2016-N-4319,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Unique Device Identification System,Notice,General Notice,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,2020-01-31T04:59:59Z,2020-01-20T02:01:08Z,2019-28246,0,0,090000648425d412
FDA-2019-P-6100-0006,FDA,FDA-2019-P-6100,Attachment E- The US Navy Tissue Bank: 50 years on the cutting edge RE: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:18:42Z,,0,0,090000648425e4df
FDA-2019-V-6105-0002,FDA,FDA-2019-V-6105,Acknowledgment Letter from FDA DMS to ETS Pro Lighting INC,Other,Acknowledgement Letter/Receipt,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T22:12:06Z,,0,0,090000648425f5f3
FDA-2019-H-6005-0001,FDA,FDA-2019-H-6005,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T17:31:45Z,,0,0,090000648425eaf3
FDA-2019-H-6022-0001,FDA,FDA-2019-H-6022,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T17:02:47Z,,0,0,090000648425e4c9
FDA-2019-H-6007-0001,FDA,FDA-2019-H-6007,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T15:55:45Z,,0,0,090000648425e289
FDA-2019-H-6020-0001,FDA,FDA-2019-H-6020,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:59:40Z,,0,0,090000648425e019
FDA-2019-H-6025-0001,FDA,FDA-2019-H-6025,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:45:46Z,,0,0,090000648425e458
FDA-2019-H-6026-0001,FDA,FDA-2019-H-6026,Complaint,Other,Complaint,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2019-12-31T16:46:40Z,,0,0,090000648425e50c
FDA-2019-N-0305-0005,FDA,FDA-2019-N-0305,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2022-10-14T13:05:41Z,2019-28249,0,0,090000648425d867
FDA-2019-P-6100-0013,FDA,FDA-2019-P-6100,Attachment P- A Randomized controlled trial comparing a human acellular dermal matrix versus conventional care for the treatment of venous leg ulcers  re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:22:17Z,,0,0,090000648425e550
FDA-2019-P-6100-0014,FDA,FDA-2019-P-6100,Attachment Q- Clinical Evaluation of Acellular Allograft Dermis for the Treatment of Human Gingival Recession re: Citizen Petition from American Association of Tissue Banks,Supporting & Related Material,Background Material,2019-12-31T05:00:00Z,2019,12,,,2020-01-06T20:22:29Z,,0,0,090000648425e551
FDA-2018-D-1459-0048,FDA,FDA-2018-D-1459,"Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics: Guidance for Industry",Other,,2019-12-31T00:00:00Z,2019,12,,,2020-01-02T20:34:48Z,,0,1,090000648425e091
EPA_FRDOC_0001-24893,EPA,EPA_FRDOC_0001,"Underground Injection Control Program; Hazardous Waste Injection Restrictions; Petition for Exemption Reissuance-Class I Hazardous Waste Injection: Great Lakes Chemical Corporation El Dorado, Arkansas Facility",Notice,,2019-12-30T05:00:00Z,2019,12,2019-12-30T05:00:00Z,,2019-12-30T12:41:42Z,2019-28209,0,0,0900006484256df8
EPA-HQ-OPPT-2019-0131-0026,EPA,EPA-HQ-OPPT-2019-0131,High-Priority Substance Designations Under the Toxic Substances Control Act and Initiation of Risk Evaluation on High-Priority Substances; Availability,Notice,,2019-12-30T05:00:00Z,2019,12,,,2019-12-30T14:40:29Z,2019-28225,0,0,0900006484256f8d
EPA-R09-OAR-2019-0321-0007,EPA,EPA-R09-OAR-2019-0321,A6. Sup.Table 1. Major Sources of NOx and VOC in Maricopa County,Supporting & Related Material,,2019-12-30T05:00:00Z,2019,12,,,2019-12-31T01:51:33Z,,0,0,09000064842158b2
EPA-R09-OAR-2019-0321-0008,EPA,EPA-R09-OAR-2019-0321,A7. Rule 324 Comment Response Support_8_28_2017,Supporting & Related Material,,2019-12-30T05:00:00Z,2019,12,,,2019-12-31T01:51:45Z,,0,0,09000064842158b3
EPA-R09-OAR-2019-0321-0027,EPA,EPA-R09-OAR-2019-0321,D5. Mojave Desert AQMD Rule 1157,Supporting & Related Material,,2019-12-30T05:00:00Z,2019,12,,,2019-12-31T01:48:22Z,,0,0,09000064842159b1